Sandwich, UK - 10 September 2025: Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.
LONDON, September 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).
Recently, Medicilon officially obtained the Good Laboratory Practice (GLP) certification certificate issued by Mexico, a member country of the OECD. In addition, we successfully passed GLP on-site inspections conducted by Hungary.
Following recent FDA and PMDA GLP audits, this achievement reaffirms that Medicilon’s preclinical research quality continues to meet the highest international standards.
Creative Biolabs delivers customized preparation solutions to solve the tough challenges facing membrane protein discovery, ensuring to yield proteins that remain functional and ready for downstream applications.
London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.
• Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital
• The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP)
Pioneer Group, a specialist in life science infrastructure and venture building, has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.
Product Marketing Lead (Life Sciences)
*Internally this role is known as Scientific Product Marketing Lead
£73,000 - £80,000plus benefits
Reports to: Head of Growth Marketing Cancer Tools
Directorate: Directorate
Contract: Permanent
Hours: Full time 35 hours per week (Flexible working requests such as compressed hours can be considered depending on business need)
Location: Stratford, London Office-based with high flexibility (1-2 days per week in the office)
Closing date: 15 September 2025 23:55
Role Overview
A leading company in the Analytical Services sector is seeking a talented ICP Scientist to join their team in the South West. In this vital role, you will provide technical expertise and support for ICP-OES and ICP-MS analytical products, playing a key part in both internal development and client-facing services. The company offers external training opportunities to support your continued professional growth.
Key Responsibilities
As the ICP Scientist, you will become a subject matter expert in your field. Your responsibilities will include:
We are recruiting a Principal Scientist, Non-Clinical PKPD, to join a leading Pharmaceutical company based in the Berkshire area for 12 months. As the Principal Scientist, Non-Clinical PKPD, you will be responsible for driving the quantitative integrated strategy of pharmacokinetics and pharmacology to bring differentiated solutions to patients.
KEY DUTIES AND RESPONSIBILITIES:
Your duties as the Principal Scientist, Non-Clinical PKPD will be varied however the key duties and responsibilities are as follows: